Renin-Angiotensin System Inhibitors Use and Risk of COVID-19

Sarfaroj Khan 

Disclosures

April 13, 2021

Takeaway

  • The use of angiotensin-converting enzyme (ACE) inhibitors in hypertensive patients was not associated with an increased risk of suspected or confirmed COVID-19, whereas the use of angiotensin II receptor blockers (ARBs) was associated with a non-significantly increased risk of COVID-19 vs calcium channel blockers (CCBs).

  • However, neither of the renin-angiotensin system (RAS) inhibitor classes was associated with a significantly increased risk of all-cause mortality during the first peak of the pandemic.

Why this matters

  • The Council on Hypertension of the European Society of Cardiology emphasised the lack of evidence supporting the harmful effects of ACE inhibitors and ARBs in the context of the COVID-19 pandemic.

Study design

  • A propensity score-matched cohort study used data from The Health Improvement Network (THIN) database in the UK.

  • There were 18,895 patients in each arm of the ACE inhibitor and CCB paired cohorts and 10,623 in each arm of the ARB and CCB paired cohorts.

  • Primary outcome was incidence of confirmed/suspected COVID-19 in each drug exposure group; secondary outcome was all-cause mortality.

  • Funding: None.

Key results

  • The incidence rates of COVID-19 were 9.3 and 9.5 per 1000 person-years in ACE inhibitor users (0.44%) and CCB users (0.45%), respectively (adjusted HR [aHR], 0.92; 95% CI, 0.68-1.26).

  • There was a non-significantly increased risk of all-cause mortality between ACE inhibitor and CCB users (aHR, 1.25; 95% CI, 0.90-1.73)

  • The incidence rates of COVID-19 were 15.8 and 11.6 per 1000 person-years in ARB users (0.74%) and CCB users (0.55%), respectively (aHR, 1.38; 95% CI, 0.98-1.95).

  • No statistically significant difference was observed in all-cause mortality between ARB and CCB users (aHR, 0.85; 95% CI, 0.56-1.30).

Limitations

  • Suspected or confirmed COVID-19 may not have been well recorded in primary care records.

 

Haroon S, Subramanian A, Cooper J, Anand A, Gokhale K, Byne N, Dhalla S, Acosta-Mena D, Taverner T, Okoth K, Wang J, Chandan JS, Sainsbury C, Zemedikun DT, Thomas GN, Parekh D, Marshall T, Sapey E, Adderley NJ, Nirantharakumar K. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care. BMC Infect Dis. 2021;21(1):262. doi: 10.1186/s12879-021-05951-w. PMID: 33722197.  View full text 

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....